News

Ranbaxy has launched its protein supplement under the brand name, Revitalite, marking its entry into the protein supplements market in India. The company claims that Revitalite offers a

Capstone Therapeutics reported a net loss of $3.1m, or $0.08 per share, for the second quarter of 2009, compared to a net loss of $2.8m or $0.07 per

CytRx has reported that INNO-206 showed to inhibit tumor growth in an experimental animal model of small cell lung cancer (SCLC). INNO-206 is a pro-drug derivative of the

Palatin Technologies (Palatin) has completed phase 1 clinical trial of bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD).

AstraZeneca and Forest Laboratories (Forest) have sealed a collaboration agreement to co-develop and commercialise ceftaroline in all markets outside the US, Canada and Japan. Ceftaroline, Forest’s late stage

Schering-Plough has launched ClaritinEye, an antihistamine eye drop, for control of itchy eyes. The company claims that ClaritinEye, an over-the-counter product, works in minutes to relieve the itch

Exact Sciences reported total revenues of $1.3m for the second quarter of 2009, compared to total revenues of $146,000 during the same period of 2008. Total revenues for

Sanofi-aventis has announced that Multaq (dronedarone) 400mg tablets received Health Canada approval for the treatment of patients with atrial fibrillation, to reduce their risk of cardiovascular hospitalization. Multaq

For the quarter, NovaDel reported a net loss of $1.7m or $0.03 per share, as compared to a net loss of $3.2m or $0.05 per share in the